Pharmacyclics expects Imbruvica sales to double

Pharmacyclics Inc. (NASDAQ:PCYC) rose $20.29 (16%) to $144 on Tuesday, gaining $1.5 billion in market cap to $10.9 billion after it said U.S. sales of oncology drug Imbruvica ibrutinib beat analyst estimates

Read the full 323 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE